Table 1.
Population characteristics
| Total N= 1152 | PDAC N= 1047 | I-IPMN N = 105 | P value | |
|---|---|---|---|---|
| Age, median (IQR) | 66 (59-73) | 66 (58-73) | 70 (62-75) | 0.003 |
| Sex, female | 521 (45) | 477 (46) | 44 (42) | 0.473 |
| I-IPMN preoperative diagnosis | ||||
| PDAC | – | – | 28 (27%) | |
| I-IPMN | – | – | 38 (36%) | |
| High risk IPMN | – | – | 39 (37%) | |
| Preop CA19.9 | 154 ± 509.2 | 157.2 ± 523.1 | 120.9 ± 336 | 0.502 |
| Active tobacco use | 136 (12) | 127 (12) | 9 (9) | 0.273 |
| Diabetes mellitus | 388 (34) | 351 (34) | 37 (35) | 0.723 |
| ECOG ≥1 | 374 (32) | 346 (33) | 28 (27) | 0.183 |
| ASA ≥3 | 798 (69) | 724 (69) | 74 (70) | 0.779 |
| Any chemotherapy | 1081 (94) | 994 (95) | 87 (83) | < 0.001 |
| Neoadjuvant CT | 704 (61) | 678 (65) | 26 (25) | < 0.001 |
|
Type of neoadjuvant CT FOLFIRINOX Gemcitabine based Other |
560 (49) 126 (11) 18 (2) |
543 (52) 118 (11) 17 (2) |
17 (16) 8 (8) 1 (1) |
0.187 |
|
Type of pancreatic resection Total pancreatectomy Pancreaticoduodenectomy Distal pancreatectomy |
143 (12) 732 (64) 277 (24) |
125 (12) 677 (65) 245 (23) |
18 (17) 55 (52) 32 (30) |
0.020 |
| Vascular resection | 396 (34) | 381 (36) | 15 (14) | < 0.001 |
| Clavien Dindo ≥3 | 380 (33) | 355 (34) | 25 (24) | 0.028 |
| 90-day mortality | 41 (4) | 38 (4) | 3 (3) | 0.684 |
Bold values indicate statistically significant results (p < 0.05)
IQR = Interquartile range, PDAC = pancreatic ductal adenocarcinoma, I-IPMN = Invasive intraductal mucinous cystic neoplasm, ECOG = eastern cooperative oncology group, ASA = American society of anesthesiology, CT = chemotherapy